<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hydralazine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hydralazine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hydralazine: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12532" href="/d/html/12532.html" rel="external">see "Hydralazine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13356" href="/d/html/13356.html" rel="external">see "Hydralazine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867124"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-HydrALAZINE;</li>
<li>Apresoline;</li>
<li>JAMP-HydrALAZINE;</li>
<li>MINT-HydrALAZINE</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F179499"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihypertensive;</li>
<li>
                        Vasodilator</li></ul></div>
<div class="block doa drugH1Div" id="F179467"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Alternative therapy for patients with persistent NYHA class III or IV heart failure with reduced ejection fraction (HFrEF) who cannot tolerate an angiotensin II receptor-neprilysin inhibitor, angiotensin-converting enzyme inhibitor, or angiotensin II receptor blocker or additional therapy in patients who have residual hypertension despite an optimal medical regimen for HFrEF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-Colucci.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-Colucci.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 mg 3 times daily in combination with isosorbide dinitrate; titrate dose as tolerated every ≥1 to 2 weeks; target dose: 75 or 100 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33446410','lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33446410','lexi-content-ref-35363499'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Not recommended for initial management but may be considered as additional therapy for resistant hypertension in patients who do not respond adequately to combination therapy with preferred agents. Consider combining with a beta-blocker and/or diuretic because hydralazine is associated with reflex tachycardia and fluid retention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>). For severe asymptomatic hypertension, may consider short-term use for BP lowering (eg, over hours) if there is concern that severe BP elevation will precipitate an acute cardiovascular event, such as in patients with known aortic or intracranial aneurysms. Some experts recommend captopril or clonidine, and hydralazine is considered an alternative agent in this situation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Varon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Varon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 10 mg 4 times daily for 2 to 4 days, then 25 mg 4 times daily for the remainder of the week followed by titration based on response to 50 mg 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); usual dosage range: 100 to 200 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>). Maximum dose: 300 mg/day in divided doses (manufacturer's labeling); however, doses &gt;200 mg/day are generally avoided due to increased risk of lupus-like reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>). Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication adjustment within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Mann.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a669e060-0890-4fb4-a8f4-02d01c746a9b">Hypertensive emergency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive emergency (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For severe elevation in blood pressure associated with new or worsening target-organ damage. Hydralazine is generally not recommended due to unpredictable and prolonged antihypertensive effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17565029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17565029'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 10 to 20 mg every 4 to 6 hours as needed; may increase dose to a maximum of 40 mg/<b>dose</b> if necessary; some experts recommend a maximum of 20 mg/<b>dose</b>. Consider combining with a beta-blocker since hydralazine is associated with reflex tachycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Elliott.1','lexi-content-ref-19635770','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Elliott.1','lexi-content-ref-19635770','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e9f708dd-ef5e-4e74-8eb4-bbad8f556048">Hypertensive emergency in pregnancy or postpartum</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive emergency in pregnancy</b>
<b> or postpartum (including acute-onset severe hypertension in preeclampsia/eclampsia)<b> (off-label use):</b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For acute-onset, severe, persistent hypertension (eg, systolic BP ≥160 mm Hg or diastolic BP ≥110 mm Hg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 5 or 10 mg; repeat with 5 to 10 mg doses every 20 to 40 minutes if BP continues to exceed thresholds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079','lexi-content-ref-35577426','lexi-content-ref-23916027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079','lexi-content-ref-35577426','lexi-content-ref-23916027'])">Ref</a></span>). If systolic BP or diastolic BP remains above threshold after a total cumulative dose of 20 to 30 mg or if heart rate exceeds 100 beats per minute, another agent should be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079','lexi-content-ref-August.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079','lexi-content-ref-August.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e806bbc-e8c4-47d7-9872-2246dddfbede">Perioperative hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Perioperative hypertension (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients with chronic hypertension prior to surgery, restart oral therapies as soon as appropriate once hemodynamically stable. The antihypertensive effects of hydralazine are less predictable than other parenteral antihypertensives and can cause reflex tachycardia. Some experts suggest doses in the low end of the dosing range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Broussard.2018','lexi-content-ref-22864917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Broussard.2018','lexi-content-ref-22864917'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 to 20 mg every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Broussard.2018','lexi-content-ref-22864917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Broussard.2018','lexi-content-ref-22864917'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991637"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> There are no dosage adjustments provided in the manufacturer's labeling. Limited data suggest concentrations of hydralazine and/or its metabolites are increased in patients with CrCl &lt;50 mL/minute; however, results vary and there is no evidence of increased adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7047041','lexi-content-ref-976304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7047041','lexi-content-ref-976304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function (Aronoff 2007; expert opinion derived from Levin 2010):</b></p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥10 mL/minute: <b>IM, IV, Oral:</b> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV:</b> No dosage adjustment necessary when used short term; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Administer usual dose every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-20016467','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-20016467','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9638393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9638393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV: </b>No dosage adjustment necessary when used short term; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Administer usual dose every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Avoid administering predialysis in patients who are prone to intra-dialytic hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27797886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27797886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9638393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9638393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV: </b>No dosage adjustment necessary when used short term; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Administer usual dose every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988930"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, hydralazine undergoes extensive hepatic metabolism.</p></div>
<div class="block doe drugH1Div" id="F179468"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F179485"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13356" href="/d/html/13356.html" rel="external">see "Hydralazine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Individualize dose; titrate to patient response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="938827fa-a54e-4b50-ac0f-91de52b8330f">Heart failure, afterload reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure, afterload reduction:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3031972','lexi-content-ref-3923176','lexi-content-ref-Park.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3031972','lexi-content-ref-3923176','lexi-content-ref-Park.2'])">Ref</a></span>): <b>Note:</b> May cause reflex tachycardia; use in combination with beta-blocker therapy has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: 0.1 to 0.5 mg/kg/dose every 6 to 8 hours; maximum dose: 2 mg/kg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: 0.15 to 0.2 mg/kg/dose every 4 to 6 hours; maximum dose: 20 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Infants, Children, and Adolescents: 0.75 to 3 mg/kg/<b>day</b> divided every 6 to 12 hours; maximum daily dose: 7 mg/kg/<b>day</b> or 200 mg/<b>day</b>, whichever is less.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b> Children and Adolescents: Oral: Initial: 0.75 mg/kg/<b>day</b> in 2 to 4 divided doses; maximum initial adult dose: 10 mg/dose; may increase gradually over 3 to 4 weeks; maximum daily dose: 7.5 mg/kg/<b>day </b>not to exceed 200 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10775081','lexi-content-ref-NHLBI.1','lexi-content-ref-Park.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10775081','lexi-content-ref-NHLBI.1','lexi-content-ref-Park.2','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9aa3b19-eddb-4745-aa9b-c76df51beb0e">Hypertension, acute severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, acute severe</b>
<b>:</b>
<b>Note: </b>Oral therapy should be used in patients with less severe symptoms; IV and IM therapy should be reserved for use in patients with life-threatening symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377'])">Ref</a></span>): Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 0.25 mg/kg/dose every 6 to 8 hours as needed; maximum dose: 25 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM, IV: Initial: 0.1 to 0.2 mg/kg/dose every 4 to 6 hours, titrate as needed; usual dosage range: 0.2 to 0.6 mg/kg/dose every 4 to 6 hours; maximum dose: 20 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-10775081','lexi-content-ref-Park.1','lexi-content-ref-21888442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-10775081','lexi-content-ref-Park.1','lexi-content-ref-21888442'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113039"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). <b>Note:</b> Renally adjusted dose recommendations are based on doses: Oral: 0.75 to 1 mg/kg/<b>day</b> divided every 6 to 12 hours; maximum daily dose: 200 mg/<b>day</b>; IV: 0.1 to 0.2 mg/kg/dose every 6 hours; maximum dose: 20 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer every 12 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent hemodialysis: Administer every 12 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis (PD): Administer every 12 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous renal replacement therapy (CRRT): Administer every 8 hours.</p></div>
<div class="block dohp drugH1Div" id="F51113040"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, hydralazine undergoes extensive hepatic metabolism.</p></div>
<div class="block arsc drugH1Div" id="F54969499"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Lupus-like syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hydralazine-induced <b>lupus-like syndrome</b> (HILS) has occurred in up to 10% of patients on doses ≥200 mg for ≥3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28194293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28194293'])">Ref</a></span>) and is reversible upon discontinuation. HILS commonly results in nonadherence or discontinuation and may lead to multi-organ involvement (pericarditis, hepatosplenomegaly); severe malaise/myalgias; acute joint pain and swelling; blood dyscrasias (leukopenia, thrombocytopenia); and positive serologies (antinuclear antibodies, antihistone antibodies, elevated erythrocyte sedimentation rate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22277146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22277146'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Exact mechanism is unknown; may occur via IL-10 suppression at higher doses of hydralazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17710582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17710582'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; onset reported after at least 3 months of therapy. However, this may vary based on dosing regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22277146','lexi-content-ref-28194293','lexi-content-ref-23316942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22277146','lexi-content-ref-28194293','lexi-content-ref-23316942'])">Ref</a></span>). Duration of therapy in case reports varies from 1 to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28932614','lexi-content-ref-28194293','lexi-content-ref-29391867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28932614','lexi-content-ref-28194293','lexi-content-ref-29391867'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22277146','lexi-content-ref-28194293','lexi-content-ref-23316942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22277146','lexi-content-ref-28194293','lexi-content-ref-23316942'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• White race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22277146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22277146'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Slow hepatic acetylation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22277146','lexi-content-ref-28194293','lexi-content-ref-23316942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22277146','lexi-content-ref-28194293','lexi-content-ref-23316942'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Doses ≥200 mg per day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28194293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28194293'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cumulative dose &gt;100 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23316942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23316942'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment for at least 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28194293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28194293'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Human leukocyte antigen DR4 genotype (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22277146','lexi-content-ref-28194293','lexi-content-ref-23316942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22277146','lexi-content-ref-28194293','lexi-content-ref-23316942'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of autoimmune disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28194293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28194293'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of thyroid disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23316942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23316942'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Null gene for C4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22277146','lexi-content-ref-23316942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22277146','lexi-content-ref-23316942'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F179429"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, edema (Cohn 2011), flushing, hypotension, myocardial stimulation, palpitations, paradoxical response to antihypertensive, tachycardia (Cohn 2011; Kandler 2011; Weingarten 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash (including eczema) (Thestrup-Pederson 1987), urticaria (Thestrup-Pederson 1987)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (Paykel 1982), constipation, diarrhea (Paykel 1982), nausea (Paykel 1982), paralytic ileus, vomiting (Paykel 1982)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Difficulty in micturition</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Andrès 2017), eosinophilia, leukopenia, lymphadenopathy, purpuric disease, splenomegaly</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Amjad 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, dizziness, headache (Cohn 2011; Paykel 1982), peripheral neuropathy (Raskin 1965; Tsujimoto 1980), psychotic reaction (including anxiety, depression, disorientation, euphoria, hypomania, nervousness) (Paykel 1982)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, muscle cramps, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, lacrimation</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, nasal congestion</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Paykel 1982)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis (Pendergraft 2014; Suneja 2014; Zuckerman 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Toxic epidermal necrolysis (Chan 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia (Kandler 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (Harati 2016; Sharma 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (Paykel 1982), malaise (Paykel 1982)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome (common: ≥10% in doses ≥200 mg for ≥3 months [Iyer 2017]; multi-organ involvement [eg, pericarditis, hepatosplenomegaly], severe malaise/myalgias, acute joint pain and swelling, blood dyscrasias [eg, leukopenia, thrombocytopenia], positive serologies [eg, antinuclear antibodies, antihistone antibodies, elevated erythrocyte sedimentation rate] [Handler 2012], and lupus erythematous-like rash [Thestrup-Pederson 1987])</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Glomerulonephritis (Bjorck 1985; Suneja 2014)</p></div>
<div class="block coi drugH1Div" id="F179444"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to hydralazine or any component of the formulation; coronary artery disease; mitral valve rheumatic heart disease</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Idiopathic systemic lupus erythematosus and related diseases; severe tachycardia and heart failure (HF) with high cardiac output (eg, in thyrotoxicosis); myocardial insufficiency due to mechanical obstruction (eg, aortic or mitral stenosis, constrictive pericarditis); isolated right ventricular HF due to pulmonary hypertension; acute dissecting aneurysm of the aorta; porphyria (injection only)</p></div>
<div class="block war drugH1Div" id="F179426"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use is contraindicated in patients with coronary artery disease (CAD). Use with caution in patients with cerebral vascular accidents and suspected CAD; myocardial stimulation produced by hydralazine can cause anginal attacks and electrocardiogram (ECG) changes of myocardial ischemia; has been implicated in the production of myocardial infarction. According to the American Heart Association/American College of Cardiology/American Society of Hypertension 2015 scientific statement for the treatment of hypertension in patients with CAD, hydralazine (without a concomitant nitrate [eg, isosorbide dinitrate]) should be avoided for the treatment of hypertension in patients with heart failure (with reduced ejection fraction) of ischemic origin (AHA/ACC/ASH [Rosendorff 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with advanced kidney impairment; dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mitral valvular disease: Use with caution in patients with mitral valvular disease; may increase pulmonary artery pressure in these patients. Use is contraindicated in patients with mitral valve rheumatic heart disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine sensitivity: May contain tartrazine, which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of tartrazine sensitivity in the general population is low, it is frequently seen in patients who are also hypersensitive to aspirin.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F54754407"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F179437"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 25 mg, 50 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F179422"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F2524631"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (hydrALAZINE HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $4.20 - $18.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (hydrALAZINE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.33 - $0.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.07 - $0.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.08 - $0.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.09 - $1.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867125"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Apresoline: 20 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 25 mg, 50 mg</p></div>
<div class="block adm drugH1Div" id="F179440"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to meals. However, food enhances bioavailability; administer consistently with regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Response may be delayed and unpredictable in some patients; titrate cautiously to response.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer undiluted as IM injection.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer undiluted as slow IV push.</p></div>
<div class="block admp drugH1Div" id="F52612988"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer without regard to meals. However, food enhances bioavailability; administer consistently with regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer undiluted as IM injection.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Administer undiluted (20 mg/mL) as slow IV push over 1 to 2 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6705171','lexi-content-ref-6459891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6705171','lexi-content-ref-6459891'])">Ref</a></span>) maximum rate: 5 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10318297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10318297'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F179438"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hypertension: </b>Management of moderate to severe hypertension. <b>Note: Not</b> recommended for the initial treatment of hypertension (ACC/AHA [Whelton 2018]).</p></div>
<div class="block off-label drugH1Div" id="F25474825"><span class="drugH1">Use: Off-Label: Adult</span><p>Heart failure with reduced ejection fraction; Hypertensive emergency in pregnancy or postpartum (including acute-onset severe hypertension in preeclampsia/eclampsia)</p></div>
<div class="block mst drugH1Div" id="F179508"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">HydrALAZINE may be confused with hydroCHLOROthiazide, HYDROmorphone, hydrOXYzine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F179495"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F179431"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of HydrALAZINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of HydrALAZINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F179460"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food enhances bioavailability of hydralazine. Management: Administer without regard to food, but keep consistent.</p></div>
<div class="block rep_considerations drugH1Div" id="F58099766"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Patients planning to become pregnant may continue taking oral hydralazine for the treatment of chronic hypertension when effective (ACC/AHA [Whelton 2018]; NICE 2019; SOGC [Magee 2022]).</p></div>
<div class="block pri drugH1Div" id="F179446"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Hydralazine crosses the placenta (Lamont 1986; Liedholm 1982).</p>
<p style="text-indent:0em;margin-top:2em;">High and frequent doses of IV hydralazine are associated with adverse events, such as maternal hypotension and fetal tachycardia, compared to other agents (ACOG 2019; ESC [Cífková 2020]; SOGC [Magee 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes and maternal acetylator status (<i>NAT2</i> genotype), some pharmacokinetic properties of oral hydralazine may be altered. Larger studies are needed to evaluate if or how these changes influence safety or efficacy during pregnancy (Han 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than oral hydralazine may be preferred (ACOG 2019; ESC [Regitz-Zagrosek 2018]); oral hydralazine is considered an alternative option due to possible side effects (SOGC [Magee 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">IV hydralazine is recommended for use in the management of acute onset, severe hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥110 mm Hg) with preeclampsia or eclampsia in pregnant and postpartum patients (ACOG 2020; ESC [Cífková 2020]; SOGC [Magee 2022]).</p></div>
<div class="block brc drugH1Div" id="F179447"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Hydralazine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of hydralazine in breast milk are available from a patient receiving oral hydralazine 50 mg 3 times a day, initiated prior to delivery. Hydralazine and metabolites were present in breast milk sampled 30 minutes after a midday dose at 8 weeks postpartum (Liedholm 1982). In a study of 4 breastfeeding women, breast milk concentrations of hydralazine were approximately one-half of maternal serum concentrations. Hydralazine was detected in the serum of their breastfeeding infants at a concentration 10 times smaller than concentrations found in a hypertensive infant being treated therapeutically with hydralazine (Lamont 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be used if administered to patients who are breastfeeding. Hydralazine is considered compatible with breastfeeding; however, sufficient data are not available following long-term use (WHO 2002).</p></div>
<div class="block mop drugH1Div" id="F179435"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure; heart rate; complete blood cell count (CBC); antinuclear antibody (ANA) titer.</p></div>
<div class="block pha drugH1Div" id="F179425"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Direct vasodilation of arterioles (with little effect on veins) with decreased systemic resistance. Although exact mechanism unknown, arterial vasodilation may occur via inhibition of calcium release from the sarcoplasmic reticulum and inhibition of myosin phosphorylation in arterial smooth muscle cells (McComb 2016).</p></div>
<div class="block phk drugH1Div" id="F179443"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IV: 10 to 80 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: IM, IV: Up to 12 hours (Marik 2007); <b>Note:</b> Duration may vary depending on acetylator status of patient. Hypotension due to hydralazine may last longer even though the circulating half-life is much shorter (Marik 2007; O’Malley 1975).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapidly absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 87%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatically acetylated; extensive first-pass effect (oral)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~22% to 69% depending on acetylator status (increased in slow acetylators and decreased in rapid acetylators) (Ludden1982); increased with food</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 3 to 7 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Oral: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51196161"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Slow acetylators: Patients will generally have higher plasma levels of hydralazine and require lower doses to maintain control of BP.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F179449"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo hydralazine | Apo-hydralazine | Apresolin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Hidral | Hydrapres</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alphapress | Apresoline</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Apresoline</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Apresolina</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Hidralazina clorhidrato | Hidralazina Clorhidrato L.CH</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Hdralzine hydrochloride</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Apresolina | Hidralazina clorhidrato</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Apresolina | Hydrapres</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Apresolina</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ardiolazin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Hydrapres</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Apresolin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Hydralazine | Hydralazine aps | Hydralazine berk | Hydralazine cox | Hydralazine dc | Hydralazine kent | Hydralazine sandoz</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apresoline</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Apresoline</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Hydralazine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Hydralazine</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Barolex</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Aprezine | Apudolomin | Asozart | Deselazin | Diucholin | Hypatol | Presfall | Propectin maruishi | Propectin organon | Solezorin | Tetrasoline | Travinon</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Hydralazine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anprasol | Hydralazine | Samjin Hydralazine HCl</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apressin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apressin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Anaprezin | Apresolina | Bionobal | Boguisina | Dilatec | Dinitryl | Folteden | Hidralazina | Hidralazina Mavi | Hidralazina solara</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo-hydralazine | Apresoline | Hydralazine</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Ak drazine | H zin | Hydralazine | Timec hydralazine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Hydralazine HCL</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Apresolin | Hydralazine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Alphapress | Apresoline | Hydralazine</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Aprezin | Hyperzine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Vaspro</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Hydralazine | Hydralazine HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Apresolina | Hidralazina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Hydraz</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-hydralazine | Apresolin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Apresolin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-hydralazine | Apresoline | Hydralazine | Hydrallazine</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">H zin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Cesoline W | Cesoline y | Dilazin | Hilazin | Hydra | Hydralazin | Hydralazine | Sanzine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Apresolin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Adernan | Apolin | Apresoline | Aprezin | Apulon | Aslozine | Asozart | Diazide | Hydralazine | Hylazine | Lotension | Naselin | Serpine | Solezorin | Susemide | Suyalin | Yajunlo</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Hydralazine</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Apresolina | Hidral</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Apresolina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Apresoline | Hydralazine | Hyperphen | Rolab-hydralazine | Sandoz hydralazine hcl</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Hydralazine HCL</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Apo-hydralazine | Hyperphen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443079">
<a name="32443079"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 222: Gestational hypertension and preeclampsia. <i>Obstet Gynecol</i>. 2020;135(6):e237-e260. doi:10.1097/AOG.0000000000003891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/32443079/pubmed" id="32443079" target="_blank">32443079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29045246">
<a name="29045246"></a>Amjad W, John G, Gulru S. Hydralazine-induced autoimmune hepatitis precipitated by the blood transfusion. <i>Am J Ther</i>. 2018;25(4):e514-e516. doi:10.1097/MJT.0000000000000605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/29045246/pubmed" id="29045246" target="_blank">29045246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28879784">
<a name="28879784"></a>Andrès E, Mourot-Cottet R. Non-chemotherapy drug-induced neutropenia - an update. <i>Expert Opin Drug Saf</i>. 2017;16(11):1235-1242. doi:10.1080/14740338.2017.1376645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/28879784/pubmed" id="28879784" target="_blank">28879784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apresoline.1">
<a name="Apresoline.1"></a>Apresoline (hydralazine) injection [product monograph]. Oakville, Ontario, Canada: SteriMax Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3031972">
<a name="3031972"></a>Artman M, Graham TP Jr. Guidelines for vasodilator therapy of congestive heart failure in infants and children. <i>Am Heart J</i>. 1987;113(4):994-1005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/3031972/pubmed" id="3031972" target="_blank">3031972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6705171">
<a name="6705171"></a>Artman M, Parrish MD, Boerth RC, Boucek RJ Jr, Graham TP Jr. Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects. <i>Circulation</i>. 1984;69(5):949-954.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/6705171/pubmed" id="6705171" target="_blank">6705171</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-August.1">
<a name="August.1"></a>August P. Treatment of hypertension in pregnant and postpartum women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6459891">
<a name="6459891"></a>Beekman RH, Rocchini AP, Rosenthal A. Hemodynamic effects of hydralazine in infants with a large ventricular septal defect. <i>Circulation</i>. 1982;65(3):523-528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/6459891/pubmed" id="6459891" target="_blank">6459891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12466730">
<a name="12466730"></a>Begum MR, Quadir E, Begum A, Akhter S, Rahman K. Management of hypertensive emergencies of pregnancy by hydralazine bolus injection vs continuous drip--a comparative study. <i>Medscape Womens Health</i>. 2002;7(5):1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/12466730/pubmed" id="12466730" target="_blank">12466730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2857437">
<a name="2857437"></a>Björck S, Westberg G, Svalander C. Hydralazine-induced glomerulonephritis. <i>Lancet</i>. 1985;1(8425):392. doi:10.1016/s0140-6736(85)91405-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/2857437/pubmed" id="2857437" target="_blank">2857437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Broussard.2018">
<a name="Broussard.2018"></a>Broussard D. Cardiovascular problems in the post-anesthesia care unit (PACU). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24588409">
<a name="24588409"></a>Chan JC, Yap DY, Yeung CK. Hydralazine-induced toxic epidermal necrolysis in a patient on continuous ambulatory peritoneal dialysis. <i>J Clin Pharm Ther</i>. 2014;39(3):322-324. doi:10.1111/jcpt.12141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/24588409/pubmed" id="24588409" target="_blank">24588409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2057035">
<a name="2057035"></a>Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. <i>N Engl J Med.</i> 1991;325(5):303-310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/2057035/pubmed" id="2057035" target="_blank">2057035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21896152">
<a name="21896152"></a>Cohn JN, McInnes GT, Shepherd AM. Direct-acting vasodilators. <i>J Clin Hypertens (Greenwich)</i>. 2011;13(9):690-692. doi:10.1111/j.1751-7176.2011.00507.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/21896152/pubmed" id="21896152" target="_blank">21896152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colucci.2020">
<a name="Colucci.2020"></a>Colucci WS. Secondary pharmacologic therapy in heart failure with reduced ejection fraction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elliott.1">
<a name="Elliott.1"></a>Elliott WJ. Drugs used for the treatment of hypertensive emergencies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/drugs-used-for-the-treatment-of-hypertensive-emergencies?search=drugs%20used%20for%20the%20treatment%20of%20hypertensive%20emergencies&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1" target="_blank">http://www.uptodate.com</a>. Accessed August 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10775081">
<a name="10775081"></a>Flynn JT. Neonatal hypertension: diagnosis and management. <i>Pediatr Nephrol</i>. 2000;14(4):332-341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/10775081/pubmed" id="10775081" target="_blank">10775081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. <i>Pediatrics</i>. 2017;140(3):e20171904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3923176">
<a name="3923176"></a>Friedman WF, George BL. Treatment of congestive heart failure by altering loading conditions of the heart. <i>J Pediatr</i>. 1985;106(5):697-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/3923176/pubmed" id="3923176" target="_blank">3923176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27797886">
<a name="27797886"></a>Georgianos PI, Agarwal R. Pharmacotherapy of hypertension in chronic dialysis patients. <i>Clin J Am Soc Nephrol</i>. 2016;11(11):2062-2075. doi:10.2215/CJN.00870116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/27797886/pubmed" id="27797886" target="_blank">27797886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23925138">
<a name="23925138"></a>Gupta VD. Chemical stability of hydralazine hydrochloride after reconstitution in 0.9% sodium chloride injection or 5% dextrose injection for infusion. <i>Int J Pharm Compd</i>. 2005;9(5):399-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/23925138/pubmed" id="23925138" target="_blank">23925138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Han.1">
<a name="Han.1"></a>Han LW, Ryu RJ, Cusumano M, et al. Effect of N-acetyltransferase 2 genotype on the pharmacokinetics of hydralazine during pregnancy. <i>J Clin Pharmacol</i>. 2019;59(12):1678-1689.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22277146">
<a name="22277146"></a>Handler J. Hydralazine-induced lupus erythematosis. <i>J Clin Hypertens (Greenwich)</i>. 2012;14(2):133-136. doi:10.1111/j.1751-7176.2011.00573.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/22277146/pubmed" id="22277146" target="_blank">22277146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26291593">
<a name="26291593"></a>Harati H, Rahmani M, Taghizadeh S. Acute cholestatic liver injury from hydralazine intake. <i>Am J Ther</i>. 2016;23(5):e1211-e1214. doi:10.1097/MJT.0000000000000310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/26291593/pubmed" id="26291593" target="_blank">26291593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28932614">
<a name="28932614"></a>Holman SK, Parris D, Meyers S, Ramirez J. Acute low-dose hydralazine-induced lupus pneumonitis. <i>Case Rep Pulmonol</i>. 2017;2017:2650142. doi:10.1155/2017/2650142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/28932614/pubmed" id="28932614" target="_blank">28932614</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Hydralazine hydrochloride tablets [prescribing information]. Hauppauge, NY; ScieGen Pharmaceuticals, Inc; February 2021.</div>
</li>
<li>
<div class="reference">
                  Hydralazine hydrochloride injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28194293">
<a name="28194293"></a>Iyer P, Dirweesh A, Zijoo R. Hydralazine induced lupus syndrome presenting with recurrent pericardial effusion and a negative antinuclear antibody. <i>Case Rep Rheumatol</i>. 2017;2017:5245904. doi:10.1155/2017/5245904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/28194293/pubmed" id="28194293" target="_blank">28194293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23370205">
<a name="23370205"></a>Jauch EC, Saver JL, Adams HP Jr, et al, "Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association," <i>Stroke</i>, 2013, 44(3):870-947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/23370205/pubmed" id="23370205" target="_blank">23370205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22071816">
<a name="22071816"></a>Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Hydralazine for essential hypertension. <i>Cochrane Database Syst Rev</i>. 2011;(11):CD004934. doi:10.1002/14651858.CD004934.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/22071816/pubmed" id="22071816" target="_blank">22071816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23316942">
<a name="23316942"></a>Keasberry J, Frazier J, Isbel NM, Van Eps CL, Oliver K, Mudge DW. Hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis presenting with a vasculitic syndrome, acute nephritis and a puzzling skin rash: a case report. <i>J Med Case Rep</i>. 2013;7:20. doi:10.1186/1752-1947-7-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/23316942/pubmed" id="23316942" target="_blank">23316942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10318297">
<a name="10318297"></a>Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/10318297/pubmed" id="10318297" target="_blank">10318297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lamont.1">
<a name="Lamont.1"></a>Lamont RF, Elder MG. Transfer of hydralazine across the placenta and into breast milk. <i>J Obstet Gynaecol</i>. 1986;7:47-48.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20016467">
<a name="20016467"></a>Levin NW, Kotanko P, Eckardt KU, et al. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. <i>Kidney Int</i>. 2010;77(4):273-284. doi:10.1038/ki.2009.469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/20016467/pubmed" id="20016467" target="_blank">20016467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7200428">
<a name="7200428"></a>Liedholm H, Wahlin-Boll E, Hanson A, et al, "Transplacental Passage and Breast Milk Concentrations of Hydralazine," <i>Eur J Clin Pharmacol</i>, 1982, 21(5):417-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/7200428/pubmed" id="7200428" target="_blank">7200428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22864917">
<a name="22864917"></a>Lien SF, Bisognano JD. Perioperative hypertension: defining at-risk patients and their management. <i>Curr Hypertens Rep</i>. 2012;14(5):432-441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/22864917/pubmed" id="22864917" target="_blank">22864917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7047041">
<a name="7047041"></a>Ludden TM, McNay JL Jr, Shepherd AM, Lin MS. Clinical pharmacokinetics of hydralazine. <i>Clin Pharmacokinet</i>. 1982;7(3):185-205. doi:10.2165/00003088-198207030-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/7047041/pubmed" id="7047041" target="_blank">7047041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33446410">
<a name="33446410"></a>Maddox TM, Januzzi JL Jr, Allen LA, et al; Writing Committee. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2021;77(6):772-810. doi:10.1016/j.jacc.2020.11.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/33446410/pubmed" id="33446410" target="_blank">33446410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17565029">
<a name="17565029"></a>Marik PE, Varon J. Hypertensive crises: challenges and management. <i>Chest.</i> 2007;131(6):1949-1962.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/17565029/pubmed" id="17565029" target="_blank">17565029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26033778">
<a name="26033778"></a>McComb MN, Chao JY, Ng TM. Direct vasodilators and sympatholytic agents. <i>J Cardiovasc Pharmacol Ther</i>. 2016;21(1):3-19. doi: 10.1177/1074248415587969.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/26033778/pubmed" id="26033778" target="_blank">26033778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.1">
<a name="NHLBI.1"></a>National Heart, Lung, and Blood Institute. Expert panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines. 2012. National Institutes of Health. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>. Accessed April 11, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2004;114(2)(suppl 4th report):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE) guideline. Hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1102235">
<a name="1102235"></a>O’Malley K, Segal JL, Israili ZH, et al. Duration of hydralazine action in hypertension. <i>Clin Pharmacol Ther</i>, 1975;18(5):581-586.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/1102235/pubmed" id="1102235" target="_blank">1102235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.2">
<a name="Park.2"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 7th ed. Elsevier Health Sciences; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6121825">
<a name="6121825"></a>Paykel ES, Fleminger R, Watson JP. Psychiatric side effects of antihypertensive drugs other than reserpine. <i>J Clin Psychopharmacol</i>. 1982;2(1):14-39. doi:10.1097/00004714-198202000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/6121825/pubmed" id="6121825" target="_blank">6121825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24276086">
<a name="24276086"></a>Pendergraft WF 3rd, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. <i>Curr Opin Rheumatol</i>. 2014;26(1):42-49. doi:10.1097/BOR.0000000000000014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/24276086/pubmed" id="24276086" target="_blank">24276086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5847557">
<a name="5847557"></a>Raskin NH, Fishman RA. Pyridoxine-deficiency neuropathy due to hydralazine. <i>N Engl J Med</i>. 1965;273(22):1182-1185. doi:10.1056/NEJM196511252732203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/5847557/pubmed" id="5847557" target="_blank">5847557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19635770">
<a name="19635770"></a>Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 1 [published correction appears in <i>Am J Health Syst Pharm</i>. 2009;66(19):168]. <i>Am J Health Syst Pharm</i>. 2009;66(15):1343-1352.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/19635770/pubmed" id="19635770" target="_blank">19635770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-98. doi: 10.1016/j.jash.2015.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29980661">
<a name="29980661"></a>Sharma M, Foge M, Mascarenhas D. A suspected case of hydralazine-induced hepatotoxicity: a case report and review of literature. <i>Am J Case Rep</i>. 2018;19:800-803.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/29980661/pubmed" id="29980661" target="_blank">29980661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9638393">
<a name="9638393"></a>St Peter WL, Clark JL, Levos OM. Drug therapy in haemodialysis patients. Special considerations in the elderly. <i>Drugs Aging</i>. 1998;12(6):441-459. doi:10.2165/00002512-199812060-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/9638393/pubmed" id="9638393" target="_blank">9638393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29808264">
<a name="29808264"></a>Starr MC, Flynn JT. Neonatal hypertension: cases, causes, and clinical approach. <i>Pediatr Nephrol</i>. 2019;34(5):787-799.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/29808264/pubmed" id="29808264" target="_blank">29808264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24561415">
<a name="24561415"></a>Suneja M, Baiswar S, Vogelgesang SA. Hydralazine associated pauci-immune glomerulonephritis. <i>J Clin Rheumatol</i>. 2014;20(2):99-102. doi:10.1097/RHU.0000000000000049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/24561415/pubmed" id="24561415" target="_blank">24561415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-976304">
<a name="976304"></a>Talseth T. Studies on hydralazine. II. Elimination rate and steady-state concentration in patients with impaired renal function. <i>Eur J Clin Pharmacol</i>. 1976;10(5):311-317. doi:10.1007/BF00565619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/976304/pubmed" id="976304" target="_blank">976304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15533851">
<a name="15533851"></a>Taylor AL, Ziesche S, Yancy C, et al; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure [published correction appears in <i>N Engl J Med</i>. 2005;352(12):1276]. <i>N Engl J Med.</i> 2004;351(20):2049-2057.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/15533851/pubmed" id="15533851" target="_blank">15533851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2893692">
<a name="2893692"></a>Thestrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. <i>Dan Med Bull</i>. 1987;34 Suppl 1:3-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/2893692/pubmed" id="2893692" target="_blank">2893692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21888442">
<a name="21888442"></a>Thomas CA. Drug treatment of hypertensive crisis in children. <i>Paediatr Drugs</i>. 2011;13(5):281-290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/21888442/pubmed" id="21888442" target="_blank">21888442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23916027">
<a name="23916027"></a>Too GT, Hill JB. Hypertensive crisis during pregnancy and postpartum period. <i>Semin Perinatol</i>. 2013;37(4):280-287.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/23916027/pubmed" id="23916027" target="_blank">23916027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6268134">
<a name="6268134"></a>Tsujimoto G, Horai Y, Ishizaki T, Itoh K. Hydralazine-induced peripheral neuropathy seen in a Japanese slow acetylator patient. <i>Br J Clin Pharmacol</i>. 1981;11(6):622-625. doi:10.1111/j.1365-2125.1981.tb01181.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/6268134/pubmed" id="6268134" target="_blank">6268134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Varon.1">
<a name="Varon.1"></a>Varon J, Elliott WJ. Management of severe asymptomatic hypertension (hypertensive urgencies) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18827911">
<a name="18827911"></a>Varon J, Marik PE. Perioperative hypertension management. <i>Vasc Health Risk Manag</i>. 2008;4(3):615-627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/18827911/pubmed" id="18827911" target="_blank">18827911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical Practice Guidelines for the Management of Hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hyperten (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30236570">
<a name="30236570"></a>Weingarten TN, Loken BL, Smith JL, et al. Incidence, course, and characteristics of hydralazine-associated tachycardia during phase I postanesthesia recovery. <i>J Perianesth Nurs</i>. 2018;33(5):632-639. doi:10.1016/j.jopan.2017.07.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/30236570/pubmed" id="30236570" target="_blank">30236570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Hypertension</i>. 2018;71(6):e140-e144]. <i>Hypertension</i>. 2018;71(6):e140-e144. doi: 10.1161/HYP.0000000000000065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17710582">
<a name="17710582"></a>Xu B, Thornton C, Makris A, Ogle R, Hennessy A. Anti-hypertensive drugs alter cytokine production from preeclamptic placentas and peripheral blood mononuclear cells. <i>Hypertens Pregnancy</i>. 2007;26(3):343-356. doi:10.1080/10641950701380958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/17710582/pubmed" id="17710582" target="_blank">17710582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29391867">
<a name="29391867"></a>Zeitjian V, Mehdizadeh A. ANA-negative hydralazine-induced pericardial effusion. <i>Case Rep Med</i>. 2017;2017:3521541. doi:10.1155/2017/3521541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/29391867/pubmed" id="29391867" target="_blank">29391867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29738027">
<a name="29738027"></a>Zuckerman R, Patel M, Costanzo EJ, et al. Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis. <i>J Bras Nefrol</i>. 2018;40(2):193-197. doi:10.1590/2175-8239-jbn-3858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydralazine-drug-information/abstract-text/29738027/pubmed" id="29738027" target="_blank">29738027</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8528 Version 474.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
